TABLE 1.

Patient Characteristics

PatientAge (y)HER2 status in primary tumor before imaging (IHC/FISH)HER2 gene amplification (determined after imaging)Primary tumor status (ER/PgR)Clinical stage before imaging
1,000 μg; mean tumor size, 28 ± 11 mm
 1681+ (IHC)FISH-ER+/PgR-IIA (T2N0M0)
 2621+ (IHC)FISH-ER+/PgR+I (T1N0M0)
 3661+ (IHC)FISH-ER+/PgR+IIA (T2N0M0)
 4480 (IHC)FISH-ER-/PgR-IIA (T2N0M0)
 5503+ (IHC)FISH+ER+/PgR+IIA (T2N0M0)
 6703+ (IHC)FISH-ER+/PgR+IIA (T2N0M0)
 7303+ (IHC)FISH+ER+/PgR+IIB (T2N1M0)
 8592+ (IHC)/FISH+ER-/PgR-IIA (T2N0M0)
 945(IHC)3+FISH-ER+/PgR-IIB (T2N1M0)
2,000 μg; mean tumor size, 25 ± 6 mm
 10501+ (IHC)FISH-ER+/PgR+IIA (T2N0M0)
 11571+ (IHC)FISH-ER+/PgR+I (T1N0M0)
 12431+ (IHC)FISH-ER+/PgR+IIA (T2N0M0)
 13511+ (IHC)FISH-ER-/PgR-IIA (T2N0M0)
 14653+ (IHC)FISH+ER+/PgR+IIA (T2N0M0)
 15353+ (IHC)FISH+ER+/PgR+I (T1N0M0)
 16501+ (IHC)*FISH+ER+/PgR+IIA (T2N0M0)
 17682+ (IHC)/FISH+ER+/PgR-IIA (T2N0M0)
 18683+ (IHC)FISH+ER+/PgR+IIA (T2N0M0)
3,000 μg; mean tumor size 22 ± 7 mm
 19371+ (IHC)FISH-ER-/PgR-IIA (T2N0M0)
 20451+ (IHC)FISH-ER+/PgR+IIA (T2N0M0)
 21561+ (IHC)FISH-ER+/PgR+IIA (T2N0M0)
 22451+ (IHC)FISH-ER+/PgR+IIA (T2N0M0)
 23361+ (IHC)FISH-ER+/PgR+IIA (T2N0M0)
 24483+ (IHC)FISH+ER+/PgR+IIВ (T2N1M0)
 25583+ (IHC)FISH+ER+/PgR+IIA (T2N0M0)
 26471+ (IHC)*FISH+ER+/PgR+IIA (T2N0M0)
 27613+ (IHC)FISH+ER+/PgR-IV (T4N3M1)
 28493+ (IHC)FISH+ER+/PgR+I (T1N0M0)
  • * Postimaging FISH evaluation demonstrated HER2 gene amplification.

  • IHC = immunohistochemistry; ER = estrogen receptor; PgR = progesterone receptor;+ = positive; - = negative.